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Fig. 1. Mean values of proteinuria as a func-
tion of the joint distribution of blood pressure.
Systolic (SBP) and diastolic (DBP) at the
screening of patients receiving angiotensin-
converting enzyme (ACE) inhibitors at con-
ventional dose (point a, 5.5 g/day), after 2-month
washout (point b, 5.6 g/day), after the up-titra-
tion period (point c, 4.0 g/day), after 2 months
of maximum dose of ramipril alone (point d,
4.0 g/day), or with indomethacin (point e, 3.9
g/day), and after recovery withdrawn (point f,
5.1 g/day).
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involvement, Dr. Piccoli and Dr. Pillon should consider
that this kind of patient responds poorly to any kind ofREFERENCES
antihypertensive/antiproteinuric therapy, as we previously1. Pisoni R, Ruggenenti P, Sangalli F, et al: Effect of high dose
reported and discussed [2]. Actually, in these patientsramipril with or without indomethacin on glomerular selectivity.
Kidney Int 62:1010–1019, 2002 we found no change in proteinuria and size selectivity
2. Ruggenenti P, Mosconi L, Sangalli F, et al: Glomerular size-
despite a significant reduction (P  0.01) in systolic/selective dysfunction in NIDDM is not ameliorated by ACE inhibi-
diastolic blood pressure from 167/99 mm Hg to 148/88tion or by calcium channel blockade. Kidney Int 55:984–994, 1999
3. Carson ER, Cobelli C: The Mathematical Modeling of Metabolic mm Hg and 150/86 mm Hg after 10 weeks perindopril
and Endocrine Systems. New York, Wiley, 1983, pp 113–230
or nitredipine therapy, respectively. These findings are
consistent with experimental evidence that ACE inhibi-
tor therapy is poorly effective in limiting the proteinuriaReply from the Authors
and the hystologic changes of diabetic nephropathy whenDr. Piccoli and Dr. Pillon have claimed that blood
treatment is started at advanced stages of the disease [3].pressure could act as an intermediate factor in the anti-
As for the validity of shunt parameter o, Dr. Piccoliproteinuric effect we achieved by maximum angiotensin-
and Dr. Pillon should consider that this is a parameterconverting enzyme (ACE) inhibition in 19 patients with
that describes the glomerular sieving function, which, innon-diabetic chronic nephropathies and nephrotic range
turn, can be influenced by changes in glomerular hemo-proteinuria. In our study, however, we found no signifi-
dynamics (in particular in glomerular transmembranecant correlation between the reduction in proteinuria
hydraulic pressure) or in the intrinsic size selectivity ofachieved after ramipril up-titration to maximum toler-
the glomerular barrier. In our study [1], we did not ex-ated doses and the concomitant reduction in blood pres-
plore the relative contribution of these two factors. Previ-sure [1]. This suggests that maximized ACE inhibition
ous studies, however, clearly demonstrated that ACErather than blood pressure reduction per se was the ma-
inhibitors ameliorate the glomerular sieving function,jor determinant of the reduction in urinary proteins.
also through a direct effect on the glomerular barrierHowever, our study was not designed to discriminate the
that is independent of the concomitant changes in sys-specific effects of ACE inhibition from those of blood
temic and glomerular pressures [4]. On the other hand,pressure reduction. To address this issue, a comparative
analysis of the antiproteinuric effect of comparable blood the statement that the calculation of omega is based on
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“arbitrary assumptions on model parameters like the of follow-up. From one 10-year-old reference is the mes-
sage that “routine measurement of vitamin B12 concentra-glomerular transmembrane hydraulic pressure and the
tions and inclusion of vitamin B12 in the supplementsultrafiltration coefficient” is uncorrect since the theoreti-
should completely eliminate . . . the risk of masking vita-cal model depends only on one assumed parameter, the
min B12 deficiency.” Because close surveillance is sug-glomerular transmembrane pressure. Assuming this pa-
gested to look for adverse effects produced from folaterameter, the value of the ultrafiltration coefficient is con-
fortification of food in the general population, which in-sequently derived. In addition, we and others have shown
creases serum folate from 10.8 to 19.0 ng/mL [2], how canthat the influence of the glomerular transmembrane pres-
we forecast that in uremic people values as high as 200sure on the calculated shunt parameter omega is negligi-
to 400 ng/mL are safe over a long time? Treatment forble [5, 6]. Thus, the criticism that no unique model can
hyperhomocysteinemia in uremic patients results in nor-be identified is not appropriate.
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Monitoring side effects in thousands of patients receiv-
To the Editor: The excellent paper by De Vriese et al ing 0.4 to 4,0 mg folate and in smaller numbers taking
in a recent issue of Kidney International on folate for large doses for several years has revealed no evidence for
cardiovascular disease in uremia largely underestimates toxicity [1, 2]. In renal failure patients, no side effects
the risk of folate overdose [1]. The suggestion that “high have been reported so far, the longest follow-up being 17
doses of folic acid are well tolerated and safe” takes root months.
Concerns about large-scale folate administration gener-from four studies with 4 to 8 weeks and 12 to 17 months
